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Abstract
Background: During stavudine phase-out plan in developing countries, tenofovir is used to substitute stavudine.
However, knowledge regarding whether there is any difference of the frequency of renal injury between tenofovir/
lamivudine/efavirenz and tenofovir/lamivudine/nevirapine is lacking.
Methods: This prospective study was conducted among HIV-infected patients who were switched NRTI from
stavudine/lamivudine to tenofovir/lamivudine in efavirenz-based (EFV group) and nevirapine-based regimen (NVP
group) after two years of an ongoing randomized trial. All patients were assessed for serum phosphorus, uric acid,
creatinine, estimated glomerular filtration rate (eGFR), and urinalysis at time of switching, 12 and 24 weeks.
Results: Of 62 patients, 28 were in EFV group and 34 were in NVP group. Baseline characteristics and eGFR were
not different between two groups. At 12 weeks, comparing mean ± SD measures between EFV group and NVP
group were: phosphorus of 3.16 ± 0.53 vs. 2.81 ± 0.42 mg/dL (P = 0.005), %patients with proteinuria were 15% vs.
38% (P = 0.050). At 24 weeks, mean ± SD phosphorus and median (IQR) eGFR between the corresponding groups
were 3.26 ± 0.78 vs. 2.84 ± 0.47 mg/dL (P = 0.011) and 110 (99-121) vs. 98 (83-112) mL/min (P = 0.008). In NVP
group, comparing week 12 to time of switching, there was a decrement of phosphorus (P = 0.007) and eGFR
(P = 0.034). By multivariate analysis, ‘receiving nevirapine’, ‘old age’ and ‘low baseline serum phosphorus’ were
associated with hypophosphatemia at 24 weeks (P < 0.05). Receiving nevirapine and low baseline eGFR were
associated with lower eGFR at 24 weeks (P < 0.05).
Conclusion: The frequency of tenofovir-associated renal impairment was higher in patients receiving tenofovir/
lamivudine/nevirapine compared to tenofovir/lamivudine/efavirenz. Further studies regarding patho-physiology are
warranted.
Introduction
The therapeutic goal of antiretroviral therapy (ART) in
human immunodeficiency virus (HIV)-infected patients
is to maintain undetectable plasma HIV viral load and
reduce HIV-associated morbidity and mortality. How-
ever, long-term exposure to ART may also be associated
with its significant toxicity [1]. Tenofovir is a nucleotide
reverse transcriptase inhibitor with potent activity
against HIV. According to the current HIV treatment
guidelines, tenofovir is one of the drugs recommended
use in the initial backbone for first-line HIV treatment
[1,2]. This drug generally has few side effects or toxici-
ties; the most common adverse events identified from
the large controlled clinical trials include skin rashes,
nausea, flatulence, diarrhea, and headache [3,4]. Tenofo-
vir is principally eliminated via the kidney; nevertheless,
minimal reductions in renal function have been reported
in the patients treated with tenofovir [5]. Severe renal
toxicity, including acute renal failure and Fanconi syn-
drome, has been reported infrequently so far [3,4,6-8].
However, it is recommended that creatinine clearance
should be calculated prior to initiating this drug as well
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phosphorus should be performed [1,9].
On the other hand, a generic fixed dose combination of
stavudine, lamivudine, and nevirapine has been widely
prescribed in resource-constrained countries until
recently [10]. Given that progressive reduction in the use
of stavudine is undertaken due to stavudine-related toxi-
cities, either tenofovir or zidovudine has been used to
substitute during stavudine phase-out plan in many
developing countries. Most of what the previous studies
show regarding tenofovir-related toxicities was studied in
a regimen of efavirenz-based or protease inhibitors-based
ART and data of tenofovir-containing backbone NRTI
plus nevirapine is scanty [11,12]. Knowledge regarding
whether there is any difference of the frequency of renal
injury after switching stavudine to tenofovir between a
regimen of tenofovir, lamivudine, and efavirenz versus
tenofovir, lamivudine, and nevirapine is still lacking.
Methods
The N2R study was a prospective, open-label, rando-
mized trial involving 142 adult Thai patients (71 patients
per group) co-infected with HIV and TB to study two
NNRTI-based ART, included efavirenz-based (EFV
group) and nevirapine-based regimen (NVP group) at
Bamrasnaradura Infectious Diseases Institute, Ministry of
Public Health, Nonthaburi, Thailand [13]. The initial
nucleoside reverse transcriptase inhibitor (NRTI) back-
bone was stavudine and lamivudine. Initial enrollment
was from December 2006 to October 2007 as previously
described [13]. The additional inclusion criteria for this
substudy were the patients who had continued with their
initial antiretroviral regimens until 96 weeks. Any patient
who had changed antiretroviral drug in the initial regi-
men due to any reason before 96 weeks was excluded. All
enrolled patients were switched NRTI backbone from
stavudine/lamivudine to tenofovir (Viread®)/lamivudine
after 96-week treatment of both NNRTI-based regimens.
They were monitored at time of switching (week 0),
12 and 24 weeks thereafter for serum phosphorus, serum
magnesium, uric acid, creatinine, estimated glomerular
filtration rate (eGFR), and urinalysis. The eGFR was cal-
culated by the Modification in Diet in Renal Disease
(MDRD) Study formula [14]. Changes in serum phos-
phorus was classified by grading system as follows:
grade1, 2.5-2.7 mg/dL; grade 2, 2.0-2.4 mg/dL; grade 3,
1.0-1.9 mg/dL and grade 4, <1.0 mg/dL.
Analyses included all patients showing at least 1 visit
after initiating tenofovir. Mean (± standard deviation, SD),
median (interquartile range at 25
th and 75
th, IQR) and fre-
quencies (%) were used to describe patients’ characteristic
as appropriate. Chi-square test and Mann-Whitney U test
were used to compare categorical and continuous variables
between the two treatment groups, respectively. Wilcoxon
Signed Ranks Test and pair-samples T test were used to
compare measures between baseline and at 12 and
24 weeks after initiating tenofovir. The independent vari-
ables were evaluated with simple linear regression to iden-
tify the factors that were associated with low serum
phosphorus level and low eGFR at week 24. By bivariate
analysis, any independent variable with P value of less
than 0.1 was included into the model of multiple regres-
sion analysis. The factors of age and serum phosphorus
were examined as continuous variables and the remaining
factors were examined as dichotomous variables. The
regression coefficients (beta value) and its 95% confidence
interval (CI) for each factor were computed. A positive
regression weights for each factor means a one-point
increase in factor results in an increase of beta value of
mg/dL of serum phosphate. A negative weight has the
opposite interpretation. Pearson’s correlations were used
to study the relationships between age and serum phos-
phorus. The Pearson’s correlation coefficient (r) and coef-
ficient of determination (r
2) were computed. All analyses
were performed using SPSS software version 15.0 (SPSS
Inc., Chicago, IL, USA). A P value less than 0.05 was con-
sidered statistically significant. The study was reviewed
and approved by the ethical review board of the Bamras-
naradura Infectious Diseases Institute and the Department
of Disease Control, Ministry of Public Health.
Results
A total of 62 patients met the inclusion criteria of this
study and all followed until the end of this study. At
week 0, all patients discontinued anti-tuberculous drugs.
Of all, 28 patients were in the EFV group and 34
patients were in the NVP group. There were no signifi-
cant differences in terms of demographic characteristics
at week 0 as shown in table 1 (P >0 . 0 5 ) .F i g u r e1c o m -
pares measures between the two groups at week 12 and
24. For serum phosphorus between the EFV group vs.
the NVP groups at week 12, proportion of patients who
had grade I were 3 (11%) vs. 8 (24%) patients; and at
week 24 were 2 (7%) vs. 6 (18%) patients, respectively.
The proportion of those who had grade II serum phos-
phorus in the corresponding groups at week 12 were 2
(9%) vs. 7 (21%) patients; and at week 24 were 3 (11%)
vs. 7 (21%) patients, respectively. The proportion of
those who had grade III serum phosphorus at week 24
were 1 (4%) and 1 (3%) patients, respectively. Figure 2
compares means and median measures between baseline
and subsequent weeks within each group. None of the
patient developed acute renal failure and Fanconi syn-
drome during the follow-up period.
Table 2 and table 3 showed univariate and multivariate
analysis of possible predicted factors that associated with
low serum phosphorus and those associated with low
eGFR at week 24 after NRTI switching. By multivariate
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nevirapine’, ‘old age’ and ‘low baseline serum phos-
phorus’, were associated with low serum phosphorus
level after 24 weeks of switching stavudine to tenofovir
(P <0 . 0 5 ) .T h ef a c t o r s‘concurrent receiving nevirapine’
and ‘low baseline eGFR’ were associated with low eGFR
at week 24 (P < 0.05). Relationship between age of
patients and combined serum phosphorus levels at week
12 and 24 after NRTI switching is depicted in figure 3.
The same trends were found at week 12 (P < 0.001,
r = -0.540) and week 24 (P < 0.001, r = -0.434). At week
24, none of the patients experienced virological rebound
or drug interruption.
Discussion
Despite tenofovir-containing NRTI backbone regimen is
effective and well tolerated, the potential for renal toxi-
city still exists, especially in the patients with vulnerable
kidney conditions [5,15,16]. The previous reviews
showed that mild tubular impairment is found in a sub-
stantial proportion of patients who treated with tenofo-
vir and tends to increase with cumulative exposure
[17-21]. However, the onset of tenofovir-associated renal
toxicity occurred widely after receiving tenofovir [22].
The present study reveals significant decreases in eGFR
within the first three months after the patients were
switched from stavudine to tenofovir. Furthermore,
decrements of eGFR progressed over time under tenofo-
vir exposure together with persistent hypophosphatemia,
lower serum uric acid level, and higher proportion of
patients with proteinuria, especially in the patients
receiving nevirapine-based ART. This is explained by
tenofovir itself primarily involves in renal tubular dys-
function and it may lead to Fanconi syndrome with or
without renal impairment. It less frequently effect on
glomerular abnormalities. This renal proximal tubular
dysfunction is manifested by decreased tubular reab-
sorption of phosphate resulting in hypophosphatemia.
Although hypophosphatemia is considerably common in
HIV-infected patients, other secondary causes of
increase in urinary loss in these stable patients with nor-
mal renal function are unlikely.
Tenofovir-associated renal dysfunction can occur as a
result of complex drug-drug interactions among antiretro-
viral drugs [22]. Most previous reports demonstrated that
this event have developed in HIV-infected patients receiv-
ing a regimen containing ritonavir-boosted protease inhi-
bitors or didanosine [22,23]. Interestingly, we found that
concomitant administration of tenofovir with two different
non-nucleoside reverse transcriptase inhibitors appeared
to have considerably different effects on renal toxicity.
Those aforementioned findings were almost not recog-
nized in the patients concurrently receiving tenofovir in an
efavirenz-based ART. Although nevirapine is extensively
metabolized via cytochrome P450 metabolism to several
hydroxylated metabolites, other isozymes may be involved
with its metabolism [24]. In a previous pharmacokinetic
study, approximately 81% of a radiolabeled dose was
recovered in the urine, with greater than 80% of that made
up of glucuronide conjugates of hydroxylated metabolites,
and less than 3% by unchanged drug [25]. On the other
hand, tenofovir disoproxil fumarate is the prodrug of the
active ingredient tenofovir. It is neither a substrate nor an
inhibitor of cytochrome enzymes, therefore low potential
for tenofovir-nevirapine interaction via the cytochrome
systems [15,16]. Tenofovir disoproxil fumarate is metabo-
lized by diester hydrolysis to tenofovir, which is then
metabolized by phosphorylation to the pharmacologically-
active metabolite tenofovir diphosphate. This drug is prin-
cipally secreted into the urine via multidrug resistance
protein (MRP) at proximal cells of renal tubule [26]. Given
that a majority of metabolite compounds of both nevira-
pine and tenofovir are eliminated via kidney, it might be
hypothesized that potential drug-drug interactions may
occur at this site. A recent study in animal model treated
with tenofovir revealed increased number and irregular
Table 1 Baseline characteristics at time of NRTI switching (week 0) between the two groups
Baseline characteristics EFV group
N=2 8
NVP group
N=3 4
P value
Gender: Female 8 (29%) 13 (38%) 0.590
Age, years, mean ± SD 35.5 ± 6.9 38.7 ± 8.3 0.110
Body weight, kilograms, mean ± SD 62.3 ± 9.8 62.7 ± 11.0 0.888
CD4 count, cells/mm
3, mean ± SD 342 ± 147 381 ± 154 0.307
Serum creatinine, mg/dL, mean ± SD 0.78 ± 0.22 0.76 ± 0.16 0.758
eGFR, mL/min, median (IQR) 116 (98-134) 105 (188-123) 0.195
Serum phosphorus, mg/dL, mean ± SD 3.0 ± 0.5 3.0 ± 0.7 0.952
Serum uric acid, mg/dL, mean ± SD 5.1 ± 1.3 5.3 ± 1.6 0.575
Serum magnesium, mg/dL, mean ± SD 0.87 ± 0.23 0.92 ± 0.20 0.391
Serum alkaline phosphatase, mg/dL, mean ± SD 87 ± 23 89 ± 24 0.743
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Table 2 Univariate and multivariate analysis of possible factors associated with low serum phosphorus at week 24
after switching NRTI
Parameters Univariate analysis Multivariate analysis
Beta 95%CI of Beta P value Beta 95%CI of Beta P value
Receiving efavirenz 0.320 0.099 to 0.739 0.011 0.321 0.098 to 0.714 0.011
Age -0.434 -0.056 to -0.017 <0.001 -0.329 -0.049 to -0.006 0.015
Serum phosphorus at week 0 0.423 0.164 to 0.720 0.002 0.298 0.023 to 0.599 0.035
Negative HBsAg -0.231 -1.278 to 0.054 0.071 0.070 -0.458 to 0.826 0.567
Female gender 0.237 -0.020 to 0.671 0.064 0.037 -0.306 to 0.405 0.781
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renal proximal tubules. Interfering the elimination of teno-
fovir may result in its accumulation and lead to toxicity.
Therefore, further studies regarding patho-physiology of
the renal impairment in tenofovir-containing backbone
NRTI plus nevirapine on this aspect are warranted. In
addition, a pharmacogenetic study revealed that poly-
morphisms in the ABCC2 gene encoding for the MRP2
was associated with proximal renal tubular dysfunction in
patients receiving tenofovir [27]. Thus, host-genetic pre-
disposition may play role.
Interestingly, significantly hypophosphatemia occurred
in the patients who concurrently received tenofovir; how-
ever, the clinical significance of these changes is not well
understood. The evidence from this study showed that
overall eGFR is substantially declined with accumulative
tenofovir exposure although no patient discontinued the
study due to renal adverse events and there were no
cases of Fanconi syndrome. An incomplete reversibility
of tenofovir-related renal toxicity, by assessing eGFR, in
HIV-infected men had been observed in a recent study
[28]. Over the past several years, stavudine has been
recommended as part of a preferred NRTI backbone in
combined with nevirapine in the resource-constrained
countries [10]. On the other hand, nevirapine-based ART
is still a key regimen to scale up treatment of HIV in
such countries [10]. Phasing out of stavudine by replaced
it with tenofovir is undertaken; therefore the policy of
close monitoring of tenofovir-associated renal toxicity for
the safety in this strategy is required. The safety issue will
be very important in many resource-constrained setting,
where laboratory monitoring is less accessible.
Identification and reversal of potentially modifiable
risk factors prior to drug use is beneficial to lower the
incidence of renal injury. As we have known that multi-
ple factors influenced in the declines in renal function
in our HIV-infected patients. The result presented here
shows that age is another factor which was associated
with hypophosphatemia; however, it was not a predictor
of declining in eGFR. The other previous reported risk
factors associated with renal toxicity included the con-
current use of other nephrotoxic medications, the use of
nonsteroidal anti-inflamma t o r yd r u g s ,t h eu s eo fap r o -
tease inhibitor, as well as co-morbidities, such as hyper-
tension and diabetes [15,16].
There are a number of limitations need to be addressed
in the present study. First, this study is not primarily
designed to assess the tenofovir-related adverse events and
association between either serum phosphorus or eGFR
and other parameters. Thus, the other potential factors
might not be well-controlled. Second, our sample size is
relatively small and the follow-up period is relatively short.
Our findings should be confirmed by a larger scale of
long-term cohort and prospective randomize trial. None-
theless, the findings revealed a tendency of an association
between receiving tenofovir-containing nevirapine-based
ART and poor renal outcomes at week 12 and 24 after
switching stavudine to tenofovir. However, this is the first
clinical trial that has shown this relationship so far. Third,
the evidence of urinary loss of phosphorus was not defi-
nitely confirmed, such as fractional excretion of phos-
phorus. As mentioned earlier, other secondary reason to
explain the persistent hypophosphatemia after a short-
period of tenofovir introduction in these stable patients
are difficult. Ultimately, the differences in demographics
and genetics may play role on the frequency of these
Table 3 Univariate and multivariate analysis of possible factors associated with low eGFR at week 24 after
switching NRTI
Parameters Univariate analysis Multivariate analysis
Beta 95%CI of Beta P value Beta 95%CI of Beta P value
eGFR at week 0 0.572 0.342 to 0.743 <0.001 0.529 0.296 to 0.707 <0.001
Receiving efavirenz 0.331 3.734 to 24.596 0.009 0.245 1.438 to 19.521 0.024
Age -0.228 -1.325 to 0.063 0.074 -0.016 -0.649 to 0.562 0.886
Figure 3 Relationship between age of patients and combined
serum phosphorus levels at week 12 and 24 after NRTI
switching. Lines represent regression prediction and 95 percent
confidence intervals for the mean. Unfilled dot represents serum
phosphorus in the EFV group; and filled dot represents serum
phosphorus in the NVP group.
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therefore, this may not be applicable to other ethnics.
In summary, the present study provides promising clini-
cal data in terms of renal impairment progresses over time
under a short period of tenofovir exposure. Moreover, the
frequency of tenofovir-associated renal impairment was
significantly higher in HIV-infected patients receiving
tenofovir/lamivudine/nevirapine compared to tenofovir/
lamivudine/efavirenz and the progress of renal impairment
in this scenario is multifactorial. Although tenofovir plus
emtricitabine or lamivudine is a preferred NRTI backbone
regimen, close monitoring of renal function by measuring
creatinine clearance and serum phosphorus is recom-
mended, particularly in the settings where laboratory
monitoring is less accessible. This finding should be vali-
dated in a larger scale of study and further studies regard-
ing patho-physiology of the renal impairment in tenofovir/
lamivudine/nevirapine needs to be explored.
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